The Online Investor
Chelsea Therapeutics International Ltd (CHTP)

Chelsea Therapeutics International is a development stage pharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products. Co. is developing Northera™ (droxidopa), a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure), dopamine-?-hydroxylase deficiency and non-diabetic autonomic neuropathy. In addition to droxidopa, Co. has a portfolio of metabolically inert antifolates that it has studied as a potential treatment of rheumatoid arthritis.
Company Name: 
Chelsea Therapeutics International Ltd
Drugs & Pharmaceuticals
Quotes delayed 20 minutes

Email EnvelopeFree CHTP Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Chelsea Therapeutics International Ltd (CHTP) Page | The Online Investor Page |

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.